Sign in

You're signed outSign in or to get full access.

AT

ATOSSA THERAPEUTICS, INC. (ATOS)·Q4 2024 Earnings Summary

Executive Summary

  • Atossa reported FY 2024 results and a strategic pivot to pursue a metastatic breast cancer indication for (Z)-endoxifen; cash and equivalents ended at $71.1M with no debt, supporting clinical execution .
  • Q4 2024 EPS of -$0.05 beat Wall Street consensus of -$0.063, marking sequential improvement from Q3 (-$0.06); revenue remained $0 given Atossa’s pre-commercial status (EPS estimates from S&P Global*).
  • Management emphasized tolerability and tumor suppression signals from EVANGELINE and full Phase 2 KARISMA-Endoxifen data, and outlined a plan to engage KOLs and the FDA over the next 4–6 months to define the registrational path in metastatic disease .
  • Key potential stock catalysts: clarity on registrational design in metastatic ER+/HER2- breast cancer, additional EVANGELINE updates, and continued cash discipline offsetting non-revenue R&D burn .

What Went Well and What Went Wrong

What Went Well

  • Strategic focus: Prioritizing a metastatic breast cancer indication to potentially streamline regulatory approval and expand into earlier-stage settings (prevention, neoadjuvant); “we believe this approach can enable a quicker route to market” .
  • Clinical signals: EVANGELINE showed substantial tumor suppression with 4-week Ki-67 ≤10% response rates generally above 85% and favorable tolerability; KARISMA-Endoxifen achieved significant MBD reductions (1 mg: -17.3 ppt; 2 mg: -23.5 ppt) with low-dose safety profile .
  • Cost discipline: FY operating expenses fell to $27.6M from $31.4M YoY as R&D and G&A compensation decreased, while maintaining cash of $71.1M for runway .

What Went Wrong

  • Limited quarterly granularity: The Q4 release focused on full-year figures without disclosing Q4 operating expenses by component, constraining quarter-over-quarter OpEx analysis .
  • Higher professional fees: G&A professional fees rose $1.8M in FY 2024 (legal, IR, accounting tied to ATM/S-3), partially offsetting compensation reductions .
  • Investment impairment: Wrote down $1.7M in equity securities (Dynamic Cell Therapies) in FY 2024 (vs. $3.0M in FY 2023), reflecting non-core asset volatility .

Financial Results

EPS vs Prior Periods and Estimates

MetricQ2 2024Q3 2024Q4 2024
EPS Actual ($USD)-$0.05 -$0.06 -$0.05*
EPS Consensus Mean ($USD)N/A-$0.06*-$0.063*
Revenue ($USD Millions)$0.00 $0.00 $0.00*

Notes: Values with asterisk (*) retrieved from S&P Global.

Full-Year Comparison (YoY)

Metric ($USD Millions unless noted)FY 2023FY 2024
Total Operating Expenses$31.38 $27.62
Net Loss$(30.09) $(25.50)
Net Loss per Share ($)-$0.24 -$0.20
Interest Income$4.34 $4.05
Cash and Equivalents$88.46 $71.08
Total Stockholders’ Equity$91.02 $71.48

KPIs and Balance Sheet Snapshots

KPIQ2 2024Q3 2024FY 2024
Cash and Equivalents ($USD Millions)$79.53 $74.77 $71.08
Shares Outstanding (millions)125.76 125.80 129.17
Current Liabilities ($USD Millions)$5.70 $5.80 $4.97

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Metastatic breast cancer program initiation pathNext 4–6 monthsNot specifiedEngage KOLs, then FDA to define registrational design; details forthcoming Introduced
EVANGELINE protocolOngoingPrior 80 mg cohort with gynecologic events disclosedAmended protocol: compare 40 mg/day + OFS vs exemestane + OFS (4-week Ki-67 endpoint); add 40 mg monotherapy 24-week Ki-67 cohort Amended
Financial guidance (revenue, margins, OpEx, OI&E, tax, dividends)2025Not providedNot provided in press release or call Maintained (no formal guidance)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024)Previous Mentions (Q3 2024)Current Period (Q4 2024)Trend
Metastatic strategyNot detailed Not detailed Strategic focus to pursue metastatic indication; streamlined path rationale Accelerating toward registrational clarity
EVANGELINE clinical progress100% disease control at 40 mg; 80 mg PK run-in completed PK/tolerability strong; Ki-67 ≤10% generally >85% Protocol amended to 40 mg + OFS vs exemestane + OFS; add monotherapy arm Refining design with favorable signal
Prevention (KARISMA-Endoxifen)Dosing completed Topline reductions in MBD (19.3%, 26.5%) Full results: -17.3 ppt (1 mg), -23.5 ppt (2 mg); low-dose safety Strengthening evidence base
Regulatory engagementNot highlightedNot highlightedPlan to consult KOLs, then FDA in 4–6 months Ramping engagement
Cost disciplineOpEx reductions vs prior year OpEx down YoY; insurance savings FY OpEx down $3.8M YoY Ongoing discipline
IP/legal and public company costs—New patent; higher legal/IR fees Legal/IR/accounting up; ATM/S-3-related costs Elevated costs tied to IP and capital markets

Management Commentary

  • “Metastatic breast cancer remains an area of critical unmet need… pursuing an initial approval in metastatic breast cancer could offer a more efficient regulatory pathway” — Steven Quay, President & CEO .
  • “We believe it could play a role across the spectrum… from early prevention to more advanced metastatic disease” — Steven Quay (prepared remarks) .
  • “We are in the process now of consulting with… KOLs… then… discussions with the FDA… over the next 4 to 6 months” — Steven Quay (Q&A) .
  • “The 4-week Ki-67 ≤10 percent response rate was generally above 85 percent… (Z)-endoxifen was well tolerated” — EVANGELINE update .
  • “Our net loss for 2024 was $25.5 million or $0.20 per share… We closed the year with $71.1 million in cash and cash equivalents” — Heather Rees, CFO .

Q&A Highlights

  • Timeline and phase for metastatic study: Company expects KOL input followed by FDA engagement over 4–6 months; study design specifics premature to disclose .
  • EVANGELINE updates: Enrollment/data timing to be shared at upcoming meetings; monotherapy vs combo Ki-67 endpoint timing clarified (24 weeks vs 4 weeks) .
  • Global approach: Focused on US FDA in 2025; international discussions likely in early next year after US design clarity .

Estimates Context

  • Q4 2024 EPS beat: -$0.05 actual vs -$0.063 consensus; Q3 2024 was in line at -$0.06 actual vs -$0.06 consensus (supports sequential improvement narrative) (EPS values from S&P Global*).
  • Revenue remains at $0 given pre-commercial status; consensus reflected $0 revenue in Q3 and Q4 (values from S&P Global*).
  • With pipeline milestones as the primary drivers and no product revenue, estimate revisions will hinge on clarity/timing of the metastatic registrational pathway and EVANGELINE updates .

Key Takeaways for Investors

  • The strategic pivot to metastatic ER+/HER2- breast cancer is the core catalyst; expect incremental updates over the next 4–6 months as KOL and FDA engagement define registrational design .
  • Clinical signals remain encouraging: EVANGELINE tumor suppression and tolerability, KARISMA low-dose efficacy on MBD with favorable safety bolster the program’s differentiated profile .
  • Cost discipline continues to extend runway despite non-revenue status; cash ended FY at $71.1M and no debt, although equity and cash declined YoY due to operating burn and impairment .
  • Near-term trading: Positive sentiment likely tied to metastatic pathway clarity and EVANGELINE protocol progress; absence of financial guidance means stock is event-driven.
  • Medium-term thesis: If registrational design and subpopulation are compelling, (Z)-endoxifen’s potency, adherence-friendly profile, and apoptosis signals could support a best-in-class narrative in endocrine therapy .
  • Watch IP/legal spend and capital markets activity (ATM/S-3) as potential overhangs, albeit manageable within current cash levels .
  • Estimate models should focus on R&D and G&A cadence, interest income trends, and milestone timing rather than revenue/margins given pre-commercial status .

Footnote: Values marked with an asterisk (*) were retrieved from S&P Global.